jaredangle
Photojournalist
Just caught this link on the front page of The Japan Times. It appears that Fuji is in the process of purchasing two of Merck's subsidiaries to give the pharmaceutical business a try, to produce new drugs to combat cancer.
http://search.japantimes.co.jp/cgi-bin/nb20110301a1.html
It's very nice to see that Fuji is stepping up to the plate to take care of these issues in a time of need, but it also struck me that this business venture is one of a much higher profit than certain elements of Fuji's film business (at least, if current health care costs in many parts of the world are an indication). Is it possible that leftover profits from the pharmaceutical business can benefit Fuji's film production, especially in a time when Neopan 1600 has been discontinued and the PRO160 series has been downsized?
Looking for your thoughts.
http://search.japantimes.co.jp/cgi-bin/nb20110301a1.html
It's very nice to see that Fuji is stepping up to the plate to take care of these issues in a time of need, but it also struck me that this business venture is one of a much higher profit than certain elements of Fuji's film business (at least, if current health care costs in many parts of the world are an indication). Is it possible that leftover profits from the pharmaceutical business can benefit Fuji's film production, especially in a time when Neopan 1600 has been discontinued and the PRO160 series has been downsized?
Looking for your thoughts.